Why the study?
Does ticagrelor reduce ischaemic events and total mortality compared to clopidogrel in patients with NSTE-ACS, independent of revascularization?
Population
Patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) with or without revascularization
Comparison
Ticagrelor vs Clopidogrel
Design
RCT
Authors
Loading...
Ticagrelor remains preferable to clopidogrel in NSTE-ACS irrespective of early revascularization; reinforces and extends PLATO consistency to non-revascularized patients.
Does ticagrelor reduce ischaemic events and total mortality compared to clopidogrel in patients with NSTE-ACS, independent of revascularization?
Ticagrelor provides consistent benefits over clopidogrel in reducing ischemic events and mortality in NSTE-ACS patients, regardless of whether they undergo revascularization within the first 10 days.
Lindholm et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: